ArticlePolymers2026
Photocrosslinkable Dexamethasone-Loaded GelMA Hydrogel for Peripheral Nerve Injury: Mechanical Behaviour and Anti-Adhesion Effect.
Article in Polymers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Peripheral nerve adhesion after surgical injury severely hinders functional nerve regeneration, leading to pain and neurological dysfunction. In this study, we developed a photocrosslinkable methacrylated gelatin (GelMA)-based hydrogel membrane that locally releases dexamethasone to simultaneously prevent adhesion and suppress inflammation. GelMA, synthesized by reacting gelatin with methacrylic anhydride, formed a stable crosslinked network, as confirmed by FT-IR spectroscopy and rheological analysis. Cytocompatibility assays showed that both GelMA and Dexa-GelMA hydrogels were non-cytotoxic to neuronal and fibroblast cell lines. In a Sprague-Dawley (SD) rat sciatic nerve injury model, implantation of the Dexa-GelMA hydrogel significantly reduced perineural adhesion and inflammation compared with the untreated control. Western blot analysis showed an approximately 80% reduction in ED-1 expression, indicating suppression of macrophage activation. Overall, the Dexa-GelMA hydrogel provides a biocompatible, multifunctional platform that integrates physical barrier function with anti-inflammatory drug delivery, showing strong potential for preventing postoperative nerve adhesion and modulating early inflammatory responses in a peripheral nerve injury model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.